A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on practolol.
OBJECTIVE
To display a ranked presentation of the data given in the Drug Analysis Prints (DAPs) provided by the MHRA/CSM so that the monitoring clinician may be readily alerted to the most important findings. The practolol DAP is taken as an example of the presentation.


METHODS
The data for the ranked system organ classes, the ranked deaths and the ranked reaction reports within each system organ class are considered separately.


RESULTS
It has been found that there are advantages in considering the system-organ classes, the deaths and the reports of the individual reactions separately and then, within these groupings, providing the mathematically ranked data. The results for practolol, withdrawn due to the associated oculomucocutaneous syndrome, are given as a single worked example.


CONCLUSIONS
Presentations of the ranked data arising from spontaneous adverse drug reactions reporting may have useful advantages.
Mann
Ronald D
RD
University of Southampton, Waterlooville, Hampshire, England. ronmann@professormann.com
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D016907:Adverse Drug Reaction Reporting Systems; D003257:Consumer Product Safety; D005128:Eye Diseases / Q000139:chemically induced / Q000453:epidemiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D017410:Practice Guidelines as Topic; D011217:Practolol / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced / Q000453:epidemiology; D013577:Syndrome; D006113:United Kingdom / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D011217:Practolol